Addiction - Pipeline Review, H2 2011

Global Markets Direct, December 2011, Pages: 149

Addiction – Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Addiction - Pipeline Review, H2 2011', provides an overview of the Addiction therapeutic pipeline. This report provides information on the therapeutic development for Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Addiction. 'Addiction - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Addiction.
- A review of the Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Addiction pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Addiction.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Addiction pipeline depth and focus of Addiction therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Addiction Therapeutic Products under Development, Key Players in Addiction Therapeutics, Addiction Pipeline Overview, Addiction Pipeline, Addiction Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Addiction Overview
Therapeutics Development
An Overview of Pipeline Products for Addiction
Addiction Therapeutics under Development by Companies
Addiction Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Addiction Therapeutics – Products under Development by Companies
Addiction Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Addiction Therapeutics Development
Johnson & Johnson
Aradigm Corporation
Shionogi & Co., Ltd.
Eli Lilly and Company
Alkermes, Inc.
Merck & Co., Inc.
Nanotherapeutics, Inc.
Nabi Biopharmaceuticals
Novartis AG
Mitsubishi Tanabe Pharma Corporation
Nippon Shinyaku Co., Ltd.
Evotec Aktiengesellschaft
AEterna Zentaris Inc.
MediciNova, Inc.
Catalyst Pharmaceutical Partners, Inc.
Cypress Bioscience, Inc
Titan Pharmaceuticals, Inc.
Biotie Therapies Corp.
Allon Therapeutics Inc.
Orexo AB
Camurus AB
Global Health Ventures Inc.
Yaupon Therapeutics, Inc.
Omeros Corporation
AIKO Biotechnology, Inc.
Embera NeuroTherapeutics, Inc.
TheraQuest Biosciences, LLC
Celtic Pharmaceutical Holdings L.P.
Beech Tree Labs, Inc.
Naurex, Inc.
Addiction – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Nalmefene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NicVAX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NS-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lofexidine + Marinol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methylphenidate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Celecoxib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Probuphine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chantix + Zyban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Memantine + Vivitrol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Depot Naltrexone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Depot Naltrexone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Propranolol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Transdermal Nicotine Replacement Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Varenicline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Topiramate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zonnic + Nicotine Patch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vareniclin + Nicotine Replacement Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Relapse Prevention Treatment + Varenicline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Revia + Campral - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Olanzapine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chantix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methadone + Dextromethorphan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methadone + Memantine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Varenicline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nicotine Patch + CBCT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Memantine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Modafinil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nabilone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Naltrexone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aripiprazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Buprenorphine + Naltrexone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Addiction Therapeutics – Drug Profile Updates
Addiction Therapeutics – Discontinued Products
Addiction – Product Development Milestones
Featured News & Press Releases
Dec 21, 2011: Lundbeck Submits European Marketing Authorization Application For Selincro For Treatment Of Alcohol Dependence
Dec 20, 2011: BioDelivery Sciences Announces Confirmation Of Final Formulation Of BEMA Buprenorphine/Naloxone Based On Positive BNX-102 Study
Dec 20, 2011: Catalyst Announces FDA Designation Of CPP-115 As Fast Track Development Program
Dec 15, 2011: Catalyst Announces Scientific Paper Regarding CPP-115 For Treatment Of Cocaine Addiction Accepted For Publication In Journal Of Medicinal Chemistry
Dec 13, 2011: NIDA To Conduct Clinical Study On Biotie's Nepicastat In Cocaine Dependence
Nov 07, 2011: Nabi Biopharmaceuticals Announces Results Of Second NicVAX Phase III Clinical Trial
Oct 28, 2011: Camurus Completes Phase I/II Trial Of CAM2038 For Treatment Of Opioid Dependence
Oct 26, 2011: Titan Pharmaceuticals Provides Probuphine Update After Meeting With FDA
Oct 20, 2011: Titan Announces Probuphine Presentation At American Society of Addiction Medicine Conference
Sep 06, 2011: BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation For Opioid Dependence
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Addiction, H2 2011
Products under Development for Addiction – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Johnson & Johnson, H2 2011
Aradigm Corporation, H2 2011
Shionogi & Co., Ltd., H2 2011
Eli Lilly and Company, H2 2011
Alkermes, Inc., H2 2011
Merck & Co., Inc., H2 2011
Nanotherapeutics, Inc., H2 2011
Nabi Biopharmaceuticals, H2 2011
Novartis AG, H2 2011
Mitsubishi Tanabe Pharma Corporation, H2 2011
Nippon Shinyaku Co., Ltd., H2 2011
Evotec Aktiengesellschaft, H2 2011
AEterna Zentaris Inc., H2 2011
MediciNova, Inc., H2 2011
Catalyst Pharmaceutical Partners, Inc., H2 2011
Cypress Bioscience, Inc, H2 2011
Titan Pharmaceuticals, Inc., H2 2011
Biotie Therapies Corp., H2 2011
Allon Therapeutics Inc., H2 2011
Orexo AB, H2 2011
Camurus AB, H2 2011
Global Health Ventures Inc., H2 2011
Yaupon Therapeutics, Inc., H2 2011
Omeros Corporation, H2 2011
AIKO Biotechnology, Inc., H2 2011
Embera NeuroTherapeutics, Inc., H2 2011
TheraQuest Biosciences, LLC, H2 2011
Celtic Pharmaceutical Holdings L.P., H2 2011
Beech Tree Labs, Inc., H2 2011
Naurex, Inc., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Addiction Therapeutics – Drug Profile Updates
Addiction Therapeutics – Discontinued Products

List of Figures
Number of Products under Development for Addiction, H2 2011
Products under Development for Addiction – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Drug Addiction - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Fatty Liver Disease - Pipeline Review, H2 2012
• Allergic Asthma - Pipeline Review, H2 2012
• Oral Mucositis - Pipeline Review, H2 2012
• Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2012
• Diabetic Nephropathy - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Insomnia - Pipeline Review, H2 2012